Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Majoven XL
- Development stage
- Unknown
- Lead developer
- Bristol Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Majoven XL is a prolonged-release capsule formulation of venlafaxine hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed and marketed by Bristol Laboratories. It is indicated for the treatment of major depressive disorder and various anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and panic disorder. The drug functions by inhibiting the reuptake of serotonin and norepinephrine through its interaction with the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby increasing neurotransmitter levels in the synaptic cleft. The prolonged-release formulation is designed for once-daily oral administration, providing sustained therapeutic exposure and improving patient compliance compared to immediate-release formulations.
- Brand names
- Majoven XL
- Other names
- Majoven XL Prolonged-Release Capsules, HardVenlafaxine Hydrochloride Prolonged-Release Capsules
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on Majoven XL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Majoven XL.